share_log

復星醫藥:海外監管公告 - 關於控股子公司借款續展暨關聯交易的公告

FOSUN PHARMA: Overseas regulatory announcement - Announcement regarding the extension of loans for holding subsidiaries and related trades.

HKEX ·  Dec 3, 2024 05:06

Summary by Moomoo AI

2024年12月3日,复星医药宣布其控股子公司复云健康的借款期限将延长12个月,至2025年12月4日。此次续展涉及的借款总额为人民币6,550万元,由复星健康、宁波复技和复星高科技分别按持股比例提供。复星健康和宁波复技的借款部分已在2023年度股东大会批准的额度范围内,而复星高科技的借款部分根据上证所《上市规则》构成关联方财务资助,但未达到董事会审议标准。复云健康成立于2021年5月,主要从事健康管理产品及服务的研发和销售。根据其管理层报表,截至2024年10月31日,复云健康的总资产为人民币856万元,负债总额为人民币9,426万元,净利润为人民币-1,117万元。此次借款续展旨在满足复云健康的日常经营需要,预计不会对复星医药集团的日常经营产生重大影响。复星医药表示,将继续密切关注复云健康的财务状况,加强风险控制和还款管理,以确保集团资金安全。此次续展借款无需另行提请董事会或股东会批准,符合公司内部管理制度和相关法规要求。
2024年12月3日,复星医药宣布其控股子公司复云健康的借款期限将延长12个月,至2025年12月4日。此次续展涉及的借款总额为人民币6,550万元,由复星健康、宁波复技和复星高科技分别按持股比例提供。复星健康和宁波复技的借款部分已在2023年度股东大会批准的额度范围内,而复星高科技的借款部分根据上证所《上市规则》构成关联方财务资助,但未达到董事会审议标准。复云健康成立于2021年5月,主要从事健康管理产品及服务的研发和销售。根据其管理层报表,截至2024年10月31日,复云健康的总资产为人民币856万元,负债总额为人民币9,426万元,净利润为人民币-1,117万元。此次借款续展旨在满足复云健康的日常经营需要,预计不会对复星医药集团的日常经营产生重大影响。复星医药表示,将继续密切关注复云健康的财务状况,加强风险控制和还款管理,以确保集团资金安全。此次续展借款无需另行提请董事会或股东会批准,符合公司内部管理制度和相关法规要求。
On December 3, 2024, Fossil Pharmaceuticals announced that the loan term of its holding subsidiary, Puyun Health, would be extended by 12 months to December 4, 2025. The loans involved in this extension amounted to RMB6,550 million and were provided by Fossil Health, Ningbo Technology and Fossil High Technology, respectively, on a per shareholding ratio. The borrowing portion of Fossil Health and Ningbo Fintech is within the range approved by the 2023 Annual General Meeting, while the borrowing portion of Fossil Hi-Tech was provided with related financial assistance under the Listing Rules of the Securities and Exchange, but did not meet the Board's approval criteria.Forumyun Health was established in May 2021, mainly concerned with the R&D and sales of health management products and services...Show More
On December 3, 2024, Fossil Pharmaceuticals announced that the loan term of its holding subsidiary, Puyun Health, would be extended by 12 months to December 4, 2025. The loans involved in this extension amounted to RMB6,550 million and were provided by Fossil Health, Ningbo Technology and Fossil High Technology, respectively, on a per shareholding ratio. The borrowing portion of Fossil Health and Ningbo Fintech is within the range approved by the 2023 Annual General Meeting, while the borrowing portion of Fossil Hi-Tech was provided with related financial assistance under the Listing Rules of the Securities and Exchange, but did not meet the Board's approval criteria.Forumyun Health was established in May 2021, mainly concerned with the R&D and sales of health management products and services. According to its management report, as of October 31, 2024, the total assets of Fujun Health were RMB856 million, total liabilities were RMB9,426 million, and net profit was RMB1,117 million. The loan extension is designed to meet the day-to-day business needs of Po Yun Health and is not expected to have a significant impact on the day-to-day operations of Star Pharmaceuticals Group.Obstar Pharmaceuticals said that it will continue to closely monitor the financial condition of Pabyu's health, strengthen risk control and refund management to ensure the safety of the Group's funds. This extension loan is subject to the Company's internal management and regulatory requirements without prior approval from the Board of Directors or Shareholders.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more